Pharmacokinetic and pharmacodynamic evaluation after administration of beclomethasone dipropionate and formoterol fumarate as fixed or free metered-dose inhaler combination in adolescent asthma

P. Kuna, G. Lucci, M. Govoni, R. Baronio, E. Carzana, A. Elgalal, I. Stelmach (Lodz, Parma, Italy; Lodz, Poland)

Source: Annual Congress 2013 –Asthma drugs: new findings
Session: Asthma drugs: new findings
Session type: Thematic Poster Session
Number: 4134
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Kuna, G. Lucci, M. Govoni, R. Baronio, E. Carzana, A. Elgalal, I. Stelmach (Lodz, Parma, Italy; Lodz, Poland). Pharmacokinetic and pharmacodynamic evaluation after administration of beclomethasone dipropionate and formoterol fumarate as fixed or free metered-dose inhaler combination in adolescent asthma. Eur Respir J 2013; 42: Suppl. 57, 4134

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013


Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013


High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013


Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients
Source: Eur Respir J 2005; 26: Suppl. 49, 180s
Year: 2005

Comparative effectiveness analysis: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate vs fluticasone propionate with spacer in children
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013


Pharmacokinetic studies for the estimation of bioequivalence of two DPIs containing budesonide and formoterol
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Efficacy of salmeterol/fluticasone propionate combination administered via Diskus inhaler in children with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 429s
Year: 2002

No age effect on systemic exposure to beclometasone and formoterol after pressurized metered dose inhalation in paediatric, adolescent and adult asthma
Source: Annual Congress 2013 –Uncontrolled and severe asthma in children
Year: 2013

Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010

Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021



PK and PD of a new beclomethasone dipropionate and formoterol CFC-free fixed combination
Source: Eur Respir J 2007; 30: Suppl. 51, 358s
Year: 2007

Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler
Source: Eur Respir J 2007; 30: Suppl. 51, 350s
Year: 2007

Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013


Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001